Implementation of Functional Diagnostics Using Patient-derived Tumor Organoids

Precision medicine aims to match individual patients with the best treatment based on the patients’ tumors biologic and molecular characteristics. As part of the Englander Institute for Precision Medicine at Weill Cornell Medical College, the Tumor Organoid Platform is an active program focused on the development of Next Generation Cancer Models derived from metastatic and primary anatomic sites obtained through biopsies, surgical resections and rapid autopsy procedures. With this platform, they are able to extend their personalized medicine program to include high throughput drug screening, which can be validated through genomic sequencing and both in vivo and in vitro models.

This webinar will review:

  • The benefits of precision medicine
  • The development of organoids as next-generation cancer models
  • The EIPM Tumor Organoid Platform pipeline

Methods suitable to large-scale production of tumor-based organoids

SPEAKER

Our Presenter:
Dr. Maria Laura Martin
Director of ex vivo models
Englander Institute for Precision Medicine
Weill Cornell Medicine

DATE 21/05/2020
TIME: 6:00pm

APUNTARSE